TY  - GEN
AU  - Shi,W
AU  - Jiang,T
AU  - Nuciforo,P
AU  - Hatzis,C
AU  - Holmes,E
AU  - Harbeck,N
AU  - Sotiriou,C
AU  - Peña,L
AU  - Loi,S
AU  - Rosa,D D
AU  - Chia,S
AU  - Wardley,A
AU  - Ueno,T
AU  - Rossari,J
AU  - Eidtmann,H
AU  - Armour,A
AU  - Piccart-Gebhart,M
AU  - Rimm,D L
AU  - Baselga,J
AU  - Pusztai,L
TI  - Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
SN  - 1569-8041
PY  - 2018///0501
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biopsy, Fine-Needle
KW  - methods
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - genetics
KW  - DNA, Neoplasm
KW  - Female
KW  - Humans
KW  - Lapatinib
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Proportional Hazards Models
KW  - Protein Kinase Inhibitors
KW  - administration & dosage
KW  - Quinazolines
KW  - Receptor, ErbB-2
KW  - antagonists & inhibitors
KW  - Trastuzumab
KW  - Exome Sequencing
KW  - rhoA GTP-Binding Protein
N1  - Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1093/annonc/mdw434
ER  -